JP2022512843A5 - - Google Patents
Info
- Publication number
- JP2022512843A5 JP2022512843A5 JP2021523243A JP2021523243A JP2022512843A5 JP 2022512843 A5 JP2022512843 A5 JP 2022512843A5 JP 2021523243 A JP2021523243 A JP 2021523243A JP 2021523243 A JP2021523243 A JP 2021523243A JP 2022512843 A5 JP2022512843 A5 JP 2022512843A5
- Authority
- JP
- Japan
- Prior art keywords
- sphingosine kinase
- aforementioned
- present
- amino acid
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811225720.2A CN109355269B (zh) | 2018-10-21 | 2018-10-21 | 鞘氨醇激酶1及其融合蛋白及其用途 |
| CN201811225720.2 | 2018-10-21 | ||
| PCT/CN2019/107091 WO2020082950A1 (zh) | 2018-10-21 | 2019-09-20 | 鞘氨醇激酶1及其融合蛋白及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512843A JP2022512843A (ja) | 2022-02-07 |
| JP2022512843A5 true JP2022512843A5 (https=) | 2023-04-05 |
Family
ID=65345959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523243A Pending JP2022512843A (ja) | 2018-10-21 | 2019-09-20 | スフィンゴシンキナーゼ１とその融合タンパク質およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210388326A1 (https=) |
| JP (1) | JP2022512843A (https=) |
| CN (1) | CN109355269B (https=) |
| WO (1) | WO2020082950A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109355269B (zh) * | 2018-10-21 | 2020-03-24 | 北京双因生物科技有限公司 | 鞘氨醇激酶1及其融合蛋白及其用途 |
| CN111303298B (zh) * | 2020-02-19 | 2023-03-21 | 李瑛� | 含有磷酸酶的融合蛋白及其产品和应用 |
| CN112143705B (zh) * | 2020-09-23 | 2022-09-06 | 北京华奥玄德生物医药科技有限公司 | 一种双基因修饰的干细胞及其用途 |
| CN114762724A (zh) * | 2020-12-31 | 2022-07-19 | 吴伯骥 | HrpWEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 |
| CN114762723A (zh) * | 2020-12-31 | 2022-07-19 | 吴伯骥 | HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 |
| CN112675293A (zh) * | 2020-12-31 | 2021-04-20 | 吴伯骥 | HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003512072A (ja) * | 1999-10-28 | 2003-04-02 | ワーナー−ランバート・カンパニー | ヒトスフィンゴシンキナーゼ遺伝子 |
| US6610534B2 (en) * | 2000-10-05 | 2003-08-26 | Novartis Ag | Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| AU2003292636A1 (en) * | 2002-12-27 | 2004-07-29 | The New Industry Research Organization | Cell growth inhibitor using sphingosine kinase 2, method of constructing fused protein having its nuclear localization signal, method of screening drug candidate, and screening kit |
| WO2014135984A2 (en) * | 2013-03-07 | 2014-09-12 | Recopharma Ab | Glycosylated mucin-immunoglobulin fusion protein coated device |
| JP6324137B2 (ja) * | 2014-03-24 | 2018-05-16 | ジヤトコ株式会社 | シール機構付き車両用無段変速機 |
| CN106279430B (zh) * | 2015-06-30 | 2017-11-28 | 安源医药科技（上海）有限公司 | Exendin‑4类似物融合蛋白及其制备方法和用途 |
| CN106432511A (zh) * | 2016-09-29 | 2017-02-22 | 上海凯茂生物医药有限公司 | GLP‑1类似物‑Fc融合蛋白及其制备方法和用途 |
| CN107875398B (zh) * | 2017-09-27 | 2021-03-23 | 浙江大学 | 一种抗体偶联药物的制备方法、抗体偶联药物及应用 |
| CN109355269B (zh) * | 2018-10-21 | 2020-03-24 | 北京双因生物科技有限公司 | 鞘氨醇激酶1及其融合蛋白及其用途 |
-
2018
- 2018-10-21 CN CN201811225720.2A patent/CN109355269B/zh active Active
-
2019
- 2019-09-20 US US17/286,445 patent/US20210388326A1/en not_active Abandoned
- 2019-09-20 JP JP2021523243A patent/JP2022512843A/ja active Pending
- 2019-09-20 WO PCT/CN2019/107091 patent/WO2020082950A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512843A5 (https=) | ||
| Halberg et al. | Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial | |
| Aronson | Meyler's side effects of drugs 15E: The international encyclopedia of adverse drug reactions and interactions | |
| Eliaschewitz et al. | Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride | |
| CN112313755B (zh) | 为基础胰岛素滴定提供剂量推荐的系统 | |
| Rodbard et al. | Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials | |
| JP2015143253A5 (https=) | ||
| CN105142661B (zh) | 通过长效胰岛素制剂治疗糖尿病 | |
| Tak et al. | Effect of oral ingestion of low-molecular collagen peptides derived from skate (Raja Kenojei) skin on body fat in overweight adults: a randomized, double-blind, placebo-controlled trial | |
| Hollander et al. | Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study) | |
| AU2016226906B2 (en) | Composition for improving or preventing nonalcoholic fatty liver | |
| Helms et al. | Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application | |
| JP2018027983A (ja) | 運動機能性向上剤 | |
| RU2011137413A (ru) | Применение кардиотрофина-1 для лечения метаболических заболеваний | |
| WO2020103889A1 (zh) | 抑郁症治疗方法和药物 | |
| JP6288757B2 (ja) | 運動機能性向上剤 | |
| CN108096568A (zh) | A型肉毒毒素在抗抑郁症中的应用 | |
| EA200600917A1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
| US20160158309A1 (en) | Exercise function enhancer | |
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| JP6565085B2 (ja) | 低血糖症状緩和剤 | |
| CN105982893B (zh) | 一种抗抑郁的组合物及其应用 | |
| Puranik | Ayurveda and Metabolic Diseases: The Whole is Greater than the | |
| CN106983742A (zh) | 一种2型糖尿病的多药联用康复冲剂及其应用 | |
| Karpenko et al. | Comparative study of the antigyperglicemic action of antidiabetic phytomedication on the model of diabetes mellitus type 2 |